| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human GPR52 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GPR52抗体的3篇参考文献(示例基于公开研究整理，非真实文献，仅供参考格式)：
---
1. **"Development of a Novel GPR52-Specific Antibody for Neuropharmacology Research"**
*Authors: Smith A, et al.*
**摘要**: 该研究报道了一种高选择性GPR52抗体的开发，通过免疫印迹和免疫组化验证其在人脑组织中的特异性，用于探索GPR52在精神疾病中的潜在作用。
2. **"GPR52 Antibody Reveals Striatal Expression Patterns in Huntington’s Disease Models"**
*Authors: Lee B, et al.*
**摘要**: 利用新开发的GPR52抗体，研究发现GPR52在纹状体神经元中高表达，并提示其可能通过调节cAMP信号通路参与亨廷顿舞蹈症的病理机制。
3. **"Targeting GPR52 with Monoclonal Antibodies for Schizophrenia Therapeutics"**
*Authors: Chen X, et al.*
**摘要**: 研究团队开发了靶向GPR52的单克隆抗体，在小鼠模型中验证其可通过拮抗受体活性改善精神分裂症相关行为，为药物研发提供新策略。
---
(注：以上文献为示例，实际文献需通过PubMed或Google Scholar检索确认。)
GPR52 (G protein-coupled receptor 52) is a class A orphan G protein-coupled receptor (GPCR) predominantly expressed in the central nervous system (CNS), particularly in regions such as the striatum, thalamus, and hippocampus. As an orphan receptor, its endogenous ligand remains unidentified, though it exhibits constitutive activity through Gαs signaling. GPR52 has garnered attention for its potential role in neuropsychiatric disorders, including schizophrenia, Huntington’s disease, and Alzheimer’s disease, as well as its involvement in dopamine and adenosine receptor signaling pathways.
Antibodies targeting GPR52 are critical tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are commonly used in techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to map receptor distribution in brain tissues or validate protein levels in cellular models. Recent studies highlight GPR52 as a therapeutic target, with agonists and antagonists being explored for modulating CNS-related conditions. However, challenges persist in ensuring antibody specificity due to GPCR structural homology and low endogenous expression levels. Validation via knockout controls or orthogonal methods is essential for reliable data. Ongoing research aims to clarify GPR52's mechanistic roles and its potential in drug development for neurological and psychiatric diseases.
×
